TWO-YEAR EFFICACY AND SAFETY OF MIRIKIZUMAB FOLLOWING 104 WEEKS OF CONTINUOUS TREATMENT: INTERIM RESULTS FROM THE LUCENT-3 OPEN-LABEL EXTENSION STUDY

被引：0

作者：

Sands, B. E. ^{[1
]}

D'haens, G. ^{[2
]}

Clemow, D. B. ^{[3
]}

Irving, P. M. ^{[4
]}

Johns, J. T. ^{[3
]}

Gibble, T. Hunter ^{[3
]}

Abreu, M. T. ^{[5
]}

Lee, S. ^{[6
]}

Hisamatsu, T. ^{[7
]}

Kobayashi, T. ^{[8
]}

Dubinsky, M. C. ^{[5
]}

Vermeire, S. ^{[9
]}

Siegel, C. A. ^{[10
]}

Peyrin-Biroulet, L. ^{[11
]}

Moses, R. E. ^{[3
]}

Milata, J. ^{[3
]}

Arora, V ^{[3
]}

Panaccione, R. ^{[12
]}

Dignass, A. ^{[13
]}

Monteleone, G. ^{[14
]}

机构：

[1] Icahn Sch Med Mt Sinai, New York, NY USA

[2] Univ Amsterdam, Med Ctr, Amsterdam, Netherlands

[3] Eli Lilly & Co, Indianapolis, IN USA

[4] Guys & St Thomas Hosp, London, England

[5] Univ Miami, Miller Sch Med, Miami, FL USA

[6] Univ Washington, Digest Hlth Ctr, Med Ctr, Seattle, WA USA

[7] Kyorin Univ, Dept Gastroenterol & Hepatol, Sch Med, Tokyo, Japan

[8] Kitasato Univ, Ctr Adv IBD Res & Treatment, Kitasato Inst Hosp, Tokyo, Japan

[9] Univ Hosp Leuven, Dept Gastroenterol & Hepatol, Leuven, Belgium

[10] Dartmouth Hitchcock Med Ctr, Lebanon, PA USA

[11] Univ Hosp Nancy Brabois, Dept Gastroenterol, Vandoeuvre Les Nancy, France

[12] Univ Calgary, Inflammatory Bowel Dis Grp, Cumming Sch Med, Calgary, AB, Canada

[13] Agaplesion Markus Krankenhaus, Frankfurt, Germany

[14] Univ Roma Tor Vergata, Dept Med Sci, Director Gastroenterol Unit, Policlin Univ Tor Vergata,Dept Syst Med, Rome, Italy

来源：

DIGESTIVE AND LIVER DISEASE | 2024年 / 56卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

BOC.04.2

引用

页码：S121 / S122

页数：2

共 50 条

[1] Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment: Interim Results From the LUCENT-3 Open-Label Extension Study
Sands, Bruce E.
D'Haens, Geert
Clemow, David B.
Irving, Peter M.
Johns, Jordan
Gibble, Theresa Hunter
Abreu, Maria T.
Lee, Scott
Hisamatsu, Tadakazu
Kobayashi, Taku
Dubinsky, Marla C.
Vermeire, Severine
Siegel, Corey A.
Peyrin-Biroulet, Laurent
Moses, Richard E.
Milata, Joe
Arora, Vipin
Panaccione, Remo
Dignass, Axel
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S627 - S627
[2] Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study
Sands, Bruce E.
D'Haens, Geert
Clemow, David B.
Irving, Peter M.
Johns, Jordan T.
Gibble, Theresa Hunter
Abreu, Maria T.
Lee, Scott
Hisamatsu, Tadakazu
Kobayashi, Taku
Dubinsky, Marla C.
Vermeire, Severine
Siegel, Corey A.
Peyrin-Biroulet, Laurent
Moses, Richard E.
Milata, Joe
Arora, Vipin
Panaccione, Remo
Dignass, Axel
INFLAMMATORY BOWEL DISEASES, 2024, 30 (12) : 2245 - 2258
[3] Long-Term Efficacy and Safety of Mirikizumab Following 152 Weeks of Continuous Treatment: Results From the LUCENT-3 Open-Label Extension Study
Sands, Bruce E.
D'Haens, Geert R.
Clemow, David
Irvin, Peter
Johns, Jordan
Gibble, Theresa
Abreu, Maria
Lee, Scott
Hisamatsu, Tadakazu
Kobayashi, Taku
Dubinsky, Marla C.
Vermeire, Severine
Siegel, Corey A.
Peyrin-Biroulet, Laurent
Moses, Richard
Milata, Joe
Arora, Vipin
Dignass, Axel
Panaccione, Remo
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10): : S1043 - S1044
[4] Three-Year Efficacy and Safety of Mirikizumab Following 152 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study
Sands, Bruce E.
D'Haens, Geert
Clemow, David B.
Irving, Peter M.
Johns, Jordan T.
Gibble, Theresa Hunter
Abreu, Maria T.
Lee, Scott D.
Hisamatsu, Tadakazu
Kobayashi, Taku
Dubinsky, Marla C.
Vermeire, Severine
Siegel, Corey A.
Peyrin-Biroulet, Laurent
Moses, Richard E.
Milata, Joe
Panaccione, Remo
Dignass, Axel
INFLAMMATORY BOWEL DISEASES, 2024,
[5] Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study (9 MAR, 10.1093/ibd/izae024, 2024 )
Sands, Bruce E.
D'Haens, Geert
Irving, Peter M.
Clemow, David B.
Johns, Jordan T.
Gibble, Theresa Hunter
Abreu, Maria T.
Lee, Scott
Hisamatsu, Tadakazu
Kobayashi, Taku
Dubinsky, Marla C.
Vermeire, Severine
Siegel, Corey A.
Peyrin-Biroulet, Laurent
Moses, Richard E.
Milata, Joe
Arora, Vipin
Panaccione, Remo
Dignass, Axel
INFLAMMATORY BOWEL DISEASES, 2024, 30 (06) : 1044 - 1045
[6] Efficacy and safety of the mirikizumab extended induction cohort at 152 weeks of continuous treatment for moderately to severely active Ulcerative Colitis: Results from the LUCENT-3 open-label extension study
Hart, A.
Blumenstein, I
Kobayashi, T.
Chaparro, M.
Fantini, M. C.
Fumery, M.
Keohane, A.
Dhesi, E.
Tian, T.
Redondo, I
Barnes, E. L.
JOURNAL OF CROHNS & COLITIS, 2025, 19 : i1452 - i1454
[7] EFFICACY AND SAFETY OF LURASIDONE IN ADOLESCENTS WITH SCHIZOPHRENIA: RESULTS OF A TWO-YEAR OPEN-LABEL EXTENSION STUDY
Goldman, Robert S.
Tocco, Michael
Pikalov, Andrei A.
Deng, Ling
Loebel, Antony
JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2018, 57 (10): : S160 - S160
[8] EFFICACY AND SAFETY OF LURASIDONE IN CHILDREN AND ADOLESCENTS WITH BIPOLAR DEPRESSION: INTERIM ANALYSIS OF A TWO-YEAR OPEN-LABEL EXTENSION STUDY
Goldman, Robert S.
DelBello, Melissa P.
Tocco, Michael
Pikalov, Andrei A.
Deng, Ling
Loebel, Antony
JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2018, 57 (10): : S137 - S137
[9] EFFICACY AND SAFETY OF 108 WEEKS' BIMEKIZUMAB TREATMENT IN PATIENTS WITH PSORIATIC ARTHRITIS: INTERIM RESULTS FROM A PHASE 2 OPEN-LABEL EXTENSION STUDY
Mcinnes, I.
Merola, J. F.
Mease, P. J.
Coates, L. C.
Joshi, P.
Coarse, J.
Ink, B.
Ritchlin, C. T.
ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 1149 - 1150
[10] Efficacy and Safety of 108 Weeks of Bimekizumab Treatment in Patients with Psoriatic Arthritis: Interim Results from a Phase 2 Open-Label Extension Study
McInnes, I. B.
Merola, J. F.
Mease, P. J.
Coates, L. C.
Schmitz, N.
Joshi, P.
Coarse, J.
Ink, B.
Ritchlin, C. T.
SWISS MEDICAL WEEKLY, 2020, : 7S - 8S

← 1 2 3 4 5 →